Oxyntomodulin: proglucagon-derived dual GLP-1/glucagon receptor agonist research overview

Oxyntomodulin (OXM) is a 37-amino acid peptide hormone derived from the preproglucagon gene, produced by intestinal L-cells and released into the bloodstream after meals alongside GLP-1, GLP-2, and glicentin. Unlike GLP-1, which was successfully developed as a therapeutic drug class (GLP-1 receptor agonists), oxyntomodulin itself never reached approved pharmaceutical use. Yet it holds a distinctive place in metabolic peptide research as the endogenous proof-of-concept for simultaneous GLP-1 receptor and glucagon receptor co-activation — a mechanistic idea that has since been deliberately engineered into synthetic dual-agonist drugs including survodutide (covered separately on Pepticker) and cotadutide. This guide examines oxyntomodulin's biology, the early clinical evidence from human trials in the 2000s, its pharmacokinetics, and why it served as the scientific ancestor of the dual-agonist drug class without ever becoming a drug itself.

What is oxyntomodulin?

Oxyntomodulin is a 37-amino acid peptide produced by post-translational processing of preproglucagon in intestinal L-cells. The preproglucagon gene encodes a large precursor protein that is processed differently depending on the tissue: in the pancreatic alpha cell, processing yields glucagon (29 amino acids); in intestinal L-cells and certain brain neurons, the same gene yields GLP-1, GLP-2, glicentin, and oxyntomodulin. Oxyntomodulin consists of the full 29-amino acid glucagon sequence followed by an 8-amino acid carboxy-terminal extension (octapeptide). It is this C-terminal extension that distinguishes oxyntomodulin from glucagon and modulates its receptor selectivity. Oxyntomodulin is released postprandially in proportion to meal caloric content and circulates at picomolar concentrations.

Oxyntomodulin is named for its original observation that it inhibits oxyntic (parietal) cell acid secretion — an effect on the gastric mucosa that gave it its name before the dual-receptor agonism was characterized. The full 37-amino acid endogenous sequence binds the glucagon receptor (GCGR) and the GLP-1 receptor (GLP-1R) with affinities roughly 10–50-fold lower than the native selective agonists (glucagon for GCGR; GLP-1 for GLP-1R). Despite this lower intrinsic potency at each individual receptor, the combined activation of both receptors produces effects on food intake, energy expenditure, and body weight that exceed those achievable by GLP-1R activation alone in preclinical models and early human studies.

Mechanism of action

Oxyntomodulin is a dual agonist at GLP-1R and GCGR, both class B (glucagon family) GPCRs coupled to Gs and adenylate cyclase. GLP-1R activation drives the familiar GLP-1 pharmacology: glucose-dependent insulin secretion, suppression of glucagon, slowed gastric emptying, central satiety signaling via vagal and brainstem pathways. GCGR activation produces a complementary and partially additive profile: increased hepatic glucose output (a concern in diabetic patients but a thermogenic benefit in non-diabetic obesity), elevated energy expenditure through increased lipolysis and hepatic fatty acid oxidation, and reduced food intake through central GCGR signaling in the hypothalamus. The glucagon component also drives brown adipose tissue thermogenesis and increases basal metabolic rate — an effect not achieved by pure GLP-1R agonists. The net result of dual GLP-1R/GCGR agonism is greater weight loss and fat mass reduction than GLP-1R agonism alone, at the cost of a need to balance glucagon-driven hyperglycemia against GLP-1-driven insulin secretion.

This mechanistic logic was the explicit conceptual basis for the subsequent development of optimized synthetic dual agonists. A landmark 2009 paper in Nature Chemical Biology (Day et al.) demonstrated the principle with a pegylated glucagon/GLP-1 co-agonist in rodent obesity models. Survodutide (BI 456906), cotadutide (MEDI0382), and other investigational dual agonists are the engineered successors to the oxyntomodulin proof of concept — designed with improved potency, selectivity tuning, and pharmacokinetic profiles.

What the research shows

The foundational human evidence for oxyntomodulin came from the laboratory of Steve Bloom and colleagues at Imperial College London. Cohen et al. (2003, J Clin Endocrinol Metab, PMID 12970330) demonstrated that intravenous infusion of oxyntomodulin reduced food intake acutely in healthy human volunteers in a double-blind crossover study. Wynne et al. (2005, Diabetes, PMID 15983207) then conducted a 4-week randomized, double-blind, placebo-controlled trial of subcutaneous oxyntomodulin injections (three times daily before meals) in 26 overweight and obese subjects. The OXM group lost a mean of 2.3 ± 0.4 kg compared to 0.5 ± 0.5 kg in the placebo group (P=0.005). Energy intake was reduced by over 25% relative to placebo. The weight loss appeared attributable to both reduced caloric intake and increased energy expenditure, consistent with the dual GLP-1R/GCGR mechanism.

A follow-up study by Wynne et al. (2006, Int J Obes) examined the mechanism of weight loss in more detail and confirmed that energy expenditure was increased — an effect attributable to glucagon receptor activity — on top of the reduction in food intake. These results were consistent with the preclinical findings showing that glucagon receptor co-activation added an energy expenditure dimension absent from GLP-1 monotherapy. However, the clinical development of oxyntomodulin itself was not pursued to phase 3 for several reasons: the peptide has a very short plasma half-life (approximately 12 minutes), requiring frequent administration; it shows moderate receptor selectivity; and the pharmaceutical industry focused instead on engineering potency-optimized long-acting synthetic dual agonists based on oxyntomodulin's mechanistic template. As a result, oxyntomodulin exists in the published literature as a validated biological proof-of-concept but not as a developed drug.

The intellectual lineage from oxyntomodulin to the current dual-agonist drug class is direct and well-documented. Researchers at Eli Lilly, Boehringer Ingelheim, AstraZeneca, and other companies have published extensively on the OXM-to-drug-candidate translation. A comprehensive review in Diabetologia (2018; PMC6448809) and a Frontiers in Endocrinology review (2021, PMID 34777014) place OXM in its historical and mechanistic context as the foundational model for what is now called the GLP-1/glucagon co-agonist class. Survodutide (covered in detail on Pepticker) is the most clinically advanced representative of this class as of 2026.

Pharmacokinetics

Endogenous and exogenous oxyntomodulin has a very short plasma half-life of approximately 12 minutes, similar to native GLP-1 and native glucagon. It is rapidly degraded by dipeptidyl peptidase-4 (DPP-4), which cleaves after the His1-Ser2 at the N-terminus, and by neutral endopeptidase. The truncated DPP-4 metabolite OXM(3–37) has substantially reduced receptor affinity. This short half-life requires frequent subcutaneous injections (three times daily in the Wynne trials) for sustained pharmacological exposure, which is fundamentally impractical as a therapeutic regimen and was a primary reason OXM itself was not developed as a drug. In contrast, modern engineered dual agonists like survodutide incorporate DPP-4-resistant N-terminal modifications and fatty acid conjugation or PEGylation to achieve weekly injection schedules.

Research dose ranges and clinical context

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

Oxyntomodulin has no approved therapeutic use in any jurisdiction and is not a commercial pharmaceutical product. The doses used in published human clinical studies were: intravenous infusion at approximately 3.0 pmol/kg/min (Cohen et al., 2003, for acute food intake suppression) and subcutaneous injection of approximately 400 nmol three times daily before meals (Wynne et al., 2005, for the 4-week weight loss trial). These doses are from research studies only and do not constitute any form of approved or recommended clinical dosing. Oxyntomodulin is not available as a pharmaceutical product; it is occasionally available from research peptide suppliers as a research-use compound, but there is no validated clinical dosing framework.

Storage and handling

Research-grade oxyntomodulin lyophilate should be stored at −20 °C in a desiccated, light-protected vial. Once reconstituted in an appropriate buffer (typically sterile saline or 0.1% acetic acid in water), the solution should be stored at 2–8 °C and used within 7 days; repeated freeze-thaw cycles should be avoided. As a 37-amino acid peptide without backbone modifications or acylation, OXM is susceptible to DPP-4 cleavage in plasma and to non-enzymatic aggregation, and reconstituted solutions should be handled with care to minimize exposure to heat and agitation.

What oxyntomodulin is NOT

Oxyntomodulin is not an approved drug. It is an endogenous peptide that reached only phase 1 and small phase 2-level human studies and was never developed into a pharmaceutical product. It should not be confused with the engineered dual GLP-1/glucagon agonist drugs — survodutide, cotadutide, and others — which are optimized synthetic molecules that use oxyntomodulin's dual-receptor concept but have been extensively re-engineered for potency, half-life, and receptor selectivity. Oxyntomodulin is also not the same as glucagon (which consists of only the first 29 amino acids shared with OXM and selectively activates GCGR), and it is not GLP-1 (which is a distinct processing product of the same preproglucagon gene, selectively activating GLP-1R). The overlap in receptor pharmacology is a consequence of shared evolutionary origin, not equivalence.

References

Key sources include Cohen et al. 2003 (J Clin Endocrinol Metab, PMID 12970330, acute food intake suppression), Wynne et al. 2005 (Diabetes, PMID 15983207, 4-week weight loss RCT), the GLP-1/glucagon co-agonism review (PMC6448809), the Frontiers in Endocrinology dual-agonist review (2021), the Day et al. 2009 Nature Chemical Biology synthetic dual-agonist rodent study, and the PMC review 'Unraveling oxyntomodulin, GLP1's enigmatic brother' (PMC3493657).